Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations
- DOI
- 10.1038/s41698-024-00634-6
- Published
- 2024-07-31
- Container
- npj Precision Oncology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41698-024-00634-6,
title = {Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations},
author = {Sarina A. Piha-Paul and Chieh Tseng and Cheuk Hong Leung and Ying Yuan and Daniel D. Karp and Vivek Subbiah and David Hong and Siqing Fu and Aung Naing and Jordi Rodon and Milind Javle and Jaffer A. Ajani and Kanwal P. Raghav and Neeta Somaiah and Gordon B. Mills and Apostolia M. Tsimberidou and Xiaofeng Zheng and Ken Chen and Funda Meric-Bernstam},
year = {2024},
journal = {npj Precision Oncology},
doi = {10.1038/s41698-024-00634-6},
url = {https://doi.org/10.1038/s41698-024-00634-6}
}RIS
TY - JOUR TI - Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations AU - Sarina A. Piha-Paul AU - Chieh Tseng AU - Cheuk Hong Leung AU - Ying Yuan AU - Daniel D. Karp AU - Vivek Subbiah AU - David Hong AU - Siqing Fu AU - Aung Naing AU - Jordi Rodon AU - Milind Javle AU - Jaffer A. Ajani AU - Kanwal P. Raghav AU - Neeta Somaiah AU - Gordon B. Mills AU - Apostolia M. Tsimberidou AU - Xiaofeng Zheng AU - Ken Chen AU - Funda Meric-Bernstam PY - 2024 JO - npj Precision Oncology DO - 10.1038/s41698-024-00634-6 UR - https://doi.org/10.1038/s41698-024-00634-6 ER -
APA
Piha-Paul, S. A., Tseng, C., Leung, C. H., Yuan, Y., Karp, D. D., Subbiah, V., Hong, D., Fu, S., Naing, A., Rodon, J., Javle, M., Ajani, J. A., Raghav, K. P., Somaiah, N., Mills, G. B., Tsimberidou, A. M., Zheng, X., Chen, K., & Meric-Bernstam, F. (2024). Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. npj Precision Oncology. https://doi.org/10.1038/s41698-024-00634-6
Source records
- crossref · retrieved 2026-09-27T06:00:15.940Z